Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India

PLoS Neglected Tropical Diseases

Volumn 8, Issue 1, 2014, Pages 44-

  Burza, Sakib ^a   Sinha, Prabhat K ^b   Mahajan, Raman ^a   Lima, María Angeles ^a   Mitra, Gaurab ^a   Verma, Neena ^b   Balsegaram, Manica ^c   Das, Pradeep ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^c MSF Access Campaign   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B; ANTIPROTOZOAL AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; FEMALE; GENDER; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; INDIA; LEISHMANIASIS RAPID TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; REINFECTION; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SPLENOMEGALY; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION; AGED; COHORT ANALYSIS; INFANT; INTRAVENOUS ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INDIA; INFANT; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84893791064     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002536     Document Type: Article

References (18)

1. WHO (2004) Global burden of disease. Available: http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html. Accessed 30 May 2013.
2. Pascual Martinez F, Picado A, Roddy P, Palma P, (2012) Low castes have poor access to visceral leishmaniasis treatment in Bihar, India. Trop Med Int Health 17: 666-673 10.1111/j.1365-3156.2012.02960.x; 10.1111/j.1365-3156.2012.02960.x.
3. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7 (5):: E35671 doi:10.1371/journal.pone.0035671.
4. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, et al. (2002) Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501.
5. Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, et al. (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53: e91-8 10.1093/cid/cir521; 10.1093/cid/cir521.
6. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: The second 10 years. Clin Microbiol Rev 21: 334-59 10.1128/CMR.00061-07; 10.1128/CMR.00061-07.
7. WHO (2010) Control of the leishmaniasis: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. Geneva: WHO Press. 202 p.
8. Kajaia M, Morse DL, Kamkamidze G, Butsashvili M, Chubabria G, et al. (2011) Risk factors for relapse of visceral leishmaniasis in Georgia. Trop Med Int Health 16: 186-192 10.1111/j.1365-3156.2010.02694.x; 10.1111/j.1365-3156.2010.02694.x.
9. Gorski S, Collin SM, Ritmeijer K, Keus K, Gatluak F, et al. (2010) Visceral leishmaniasis relapse in southern Sudan (1999-2007): A retrospective study of risk factors and trends. PLoS Negl Trop Dis 4: e705 10.1371/journal.pntd.0000705; 10.1371/journal.pntd.0000705.
10. Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, et al. (2010) Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83: 357-364 10.4269/ajtmh.2010.10-0156.
11. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, et al. (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17: 493-510 10.1517/14728214.2012.748036; 10.1517/14728214.2012.748036.
12. Ministry of Home Affairs, Government of India (2011) Census of India 2011. Available: http://www.censusindia.gov.in/2011-prov-results/PPT_2.html. Accessed 3 June 2013.
13. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, et al. (2013) Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56: 1530-1538 10.1093/cid/cit102; 10.1093/cid/cit102.
14. National Vector Borne Disease Control Programme (2013) "Kala-azar Cases and Deaths in the Country since 2007." Available: http://www.nvbdcp.gov.in/ka-cd.html. Accessed 20 May 2013.
15. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, et al. (2008) Pharmacokinetics of miltefosine in old world cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52: 2855-2860 10.1128/AAC.00014-08; 10.1128/AAC.00014-08.
16. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, et al. (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543-550 10.1093/cid/cis474; 10.1093/cid/cis474.
17. Burza S, Nabi E, Mahajan R, Mitra G, Lima MA, (2013) One-Year Follow-up of Immunocompetent Male Patients Treated With Miltefosine For Primary Visceral Leishmaniasis in Bihar, India. Clin Infect Dis 57 (9):: 1363-4 doi:10.1093/cid/cit508.
18. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, (2010) Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504-512 10.1056/NEJMoa0903627; 10.1056/NEJMoa0903627.